{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:14:25Z","timestamp":1791461665508,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0331"],"award-info":[{"award-number":["W81XWH-22-1-0331"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01740-0","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T04:17:06Z","timestamp":1752293826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting the oncoprotein RLIP as novel therapy for ovarian cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"B. Madhu","family":"Krishna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-8160","authenticated-orcid":false,"given":"Sharad S.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"1740_CR1","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376\u201388.","journal-title":"Lancet"},{"key":"1740_CR2","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","volume":"20","author":"AC Veneziani","year":"2023","unstructured":"Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, Madariaga A, Bhat G, Rouzbahman M, Sneha S, Oza AM. Heterogeneity and treatment landscape of ovarian carcinoma. Nat Rev Clin Oncol. 2023;20:820\u201342.","journal-title":"Nat Rev Clin Oncol"},{"key":"1740_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan S. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21:389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"key":"1740_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with Paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1\u20136.","journal-title":"N Engl J Med"},{"key":"1740_CR5","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1158\/0008-5472.CAN-05-3534","volume":"66","author":"SS Singhal","year":"2006","unstructured":"Singhal SS, Awasthi YC, Awasthi S. Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res. 2006;66:2354\u201360.","journal-title":"Cancer Res"},{"key":"1740_CR6","first-page":"37804871","volume-title":"Regression of ovarian cancer xenografts by depleting or inhibiting RLIP","author":"S Ramisetty","year":"2023","unstructured":"Ramisetty S, Garg P, Mohanty A, Mirzapoiazova T, Yue E, Wang E, Horne D, Awasthi S, Kulkarni P, Salgia R, Singhal SS. Regression of ovarian cancer xenografts by depleting or inhibiting RLIP. (PMID: Biochem Pharmacol; 2023. p. 37804871."},{"key":"1740_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/carcin\/bgae047","volume":"45","author":"BM Krishna","year":"2024","unstructured":"Krishna BM, Ramisetty SK, Garg P, Mohanty A, Wang E, Horne D, Awasthi S, Kulkarni P, Salgia R, Singhal SS. Enhancing carboplatin sensitivity in ovarian cancer cells by blocking the mercapturic acid pathway transporter. Carcinogenesis. 2024;45:696\u2013707.","journal-title":"Carcinogenesis"},{"key":"1740_CR8","doi-asserted-by":"publisher","first-page":"9327","DOI":"10.1021\/bi992964c","volume":"39","author":"S Awasthi","year":"2000","unstructured":"Awasthi S, Cheng J, Singhal SS, Saini MK, Pandya U, Pikula S, Pikula J, Singh SV, Zimniak P, Awasthi YC. Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin. Biochemistry. 2000;39:9327\u201334.","journal-title":"Biochemistry"},{"key":"1740_CR9","doi-asserted-by":"publisher","first-page":"19714","DOI":"10.1074\/jbc.M708703200","volume":"28","author":"SS Singhal","year":"2008","unstructured":"Singhal SS, Yadav S, Drake K, Singhal J, Awasthi S. Hsf-1 and POB1 induce drug-sensitivity and apoptosis by inhibiting Ralbp1. J Biol Chem. 2008;28:19714\u201329.","journal-title":"J Biol Chem"},{"key":"1740_CR10","doi-asserted-by":"publisher","first-page":"102021","DOI":"10.1016\/j.ctrv.2020.102021","volume":"86","author":"TT Huang","year":"2020","unstructured":"Huang TT, Lampert EJ, Coots C, Lee JM. Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer. Cancer Treat Rev. 2020;86:102021.","journal-title":"Cancer Treat Rev"},{"key":"1740_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ygyno.2021.09.023","volume":"163","author":"J Liu","year":"2021","unstructured":"Liu J, Burris H, Wang JS, Barroilhet L, Gutierrez M, Wang Y, Vaze A, Commerford R, Royer-Joo S, Choeurng V, et al. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2021;163:473\u201380.","journal-title":"Gynecol Oncol"},{"key":"1740_CR12","doi-asserted-by":"publisher","first-page":"e25976","DOI":"10.2196\/25976","volume":"7","author":"SP Yang","year":"2021","unstructured":"Yang SP, Su HL, Chen XB, Hua L, Chen JX, Hu M, Lei J, Wu S-G, Zhou J. Long-term survival among histological subtypes in advanced epithelial ovarian cancer: population-based study using the surveillance, epidemiology, and end results database. JMIR Public Health Surveill. 2021;7:e25976.","journal-title":"JMIR Public Health Surveill"},{"key":"1740_CR13","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/bjc.2016.311","volume":"115","author":"GE Konecny","year":"2016","unstructured":"Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer. 2016;115:1157\u201373.","journal-title":"Br J Cancer"},{"key":"1740_CR14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/AOG.0b013e318264f794","volume":"120","author":"LA Baldwin","year":"2012","unstructured":"Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, Nagell JRV, Seamon LG. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120:612\u20138.","journal-title":"Obstet Gynecol"},{"key":"1740_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ijc.11260","volume":"106","author":"S Awasthi","year":"2003","unstructured":"Awasthi S, Singhal SS, Sharma R, Zimniak P, Awasthi YC. Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): A novel link between G-protein and tyrosine kinase signaling and drug resistance. Int J Cancer. 2003;106:635\u201346.","journal-title":"Int J Cancer"},{"key":"1740_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1593\/neo.101080","volume":"12","author":"Z Wu","year":"2010","unstructured":"Wu Z, Owens C, Chandra N, Popovic K, Conaway M, Theodorescu D. RalBP1 is necessary for metastasis of human Cancer cell lines. Neoplasia. 2010;12:1003\u201312.","journal-title":"Neoplasia"},{"key":"1740_CR17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.bbrc.2014.10.114","volume":"454","author":"S Lee","year":"2014","unstructured":"Lee S, Wurtzel JGT, Goldfinger LE. The RLIP76 N-terminus binds ARNO to regulate PI 3-kinase, Arf6 and Rac signaling, cell spreading and migration. Biochem Biophys Res Commun. 2014;454:560\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"1740_CR18","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-05-0968","volume":"65","author":"S Awasthi","year":"2005","unstructured":"Awasthi S, Singhal SS, Yadav S, Singhal J, Drake K, Nadkar A, Zajac E, Wickrarachchi D, Rowe N, Yacoub A, et al. RLIP76 is a major determinant of radiation sensitivity. Cancer Res. 2005;65:6022\u20138.","journal-title":"Cancer Res"},{"key":"1740_CR19","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/1078-0432.CCR-08-0145","volume":"14","author":"S Awasthi","year":"2008","unstructured":"Awasthi S, Singhal SS, Awasthi YC, Martin B, Woo J-H, Cunningham C, Frankel AE. RLIP76 and cancer. Clin Cancer Res. 2008;14:4372\u20137.","journal-title":"Clin Cancer Res"},{"key":"1740_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-0-387-68969-2_4","volume":"622","author":"CA Barton","year":"2008","unstructured":"Barton CA, Clark SJ, Hacker NF, O\u2019Brien PM. Epigenetic markers of ovarian cancer. Adv Exp Med Biol. 2008;622:35\u201351.","journal-title":"Adv Exp Med Biol"},{"key":"1740_CR21","unstructured":"Ovarian Cancer - Cancer Stat Facts. [cited 2023 Aug 10]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01740-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01740-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01740-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T06:11:16Z","timestamp":1757225476000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01740-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1740"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01740-0","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human participants were not part of this study. The research involving animals followed IACUC protocol #22011, which gained approval from the City of Hope Animal Care and Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Participation consent and ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We demonstrate that RLIP is essential for ovarian cancer formation, its expression is significantly higher in ovarian cancer cells than in non-malignant cells, and its depletion or inhibition prevents ovarian carcinogenesis and metastases.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"One sentence summary"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}